TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04076332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Decision aid is a tool that helps patients become involved in decision making on choosing treatment plans. Decision aid provides information about the options and outcomes, and by clarifying personal values.
Study: NCT03488329

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individual nutritional therapy
Description: Guidance from a clinical dietician.~Individual nutrition plan~A package containing foods and drinks, which will cover their nutritional needs the first day after discharge.~A goodiebag containing samples on protein-rich milk-based drinks.~Telephone follow-up after 4 and 30 days and the possibility to call the dietician in case of questions about nutrition.
Study: NCT01870869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
Description: Surgical implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
Description: Surgical implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
Description: Surgical implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
Description: Surgical implant
Study: NCT01569412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ertumaxomab
Description: trifunctional antibody, infusion i.v., increasing doses, up to 10 infusions
Study: NCT03221478

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping placebo and exercises
Description: Kinesio Taping placebo and exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping with tension and exercises
Description: Kinesio Taping with tension and exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping with tension
Description: Kinesio Taping with tension
Study: NCT01566357

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fluoridated Milk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Mousse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MI Paste Plus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elmex Erosion Protection
Study: NCT02991430

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active neuromodulation for episodic migraine headache
Description: Non-invasive brainstem neuromodulator. Active and placebo devices appear identical

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo neuromodulation for episodic migraine headache
Description: Sham non-invasive brainstem neuromodulator. Active and placebo devices appear identical
Study: NCT01434862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Closed loop with pramlintide
Description: Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop without pramlintide
Description: This visit will assess how well the closed loop system works without the pramlintide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open loop with pramlintide
Description: Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
Study: NCT03022812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck-specific exercise
Description: Neck-specific exercise
Study: NCT01926132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid 10g/20ml
Description: ascorbic acid 10g/20cc intravenous injection for 40mins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline 150ml
Description: Normal Saline 150ml intravenous injection for 40mins
Study: NCT04849637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil
Description: Oral supplementation of virgin coconut oil to COVID-19 patients
Study: NCT02248896

Intervention type: DRUG
Intervention: Telmisartan

Intervention type: DRUG
Intervention: Other angiotensin-receptor blockers (ARBs)
Study: NCT03022812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise
Description: Neck-specific exercise
Study: NCT02248896

Intervention type: DRUG
Intervention: Angiotensin-converting enzyme inhibitors (ACEIs)

Intervention type: DRUG
Intervention: Other major antihypertensive medication classes
Description: e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
Study: NCT00399035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: oral tablet
Study: NCT04041908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Product
Description: 2 sachets per day
Study: NCT00399035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: intravenous infusion
Study: NCT01204333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endovascular thrombolysis
Description: Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
Study: NCT00399035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX (Capecitabine and Oxaliplatin)
Description: intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)
Study: NCT00304915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care Interventions
Description: Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
Study: NCT01078714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bumetanide
Description: Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bumetanide
Description: Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
Study: NCT03819218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 cream
Description: MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)
Study: NCT03104998

Intervention type: DRUG
Group type: OTHER
Intervention: Coenzyme Q10
Description: 200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
Study: NCT00821665

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose consumption
Description: Sucrose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: water consumption
Description: water
Study: NCT03002103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Study: NCT00598715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stent
Description: Sirolimus-eluting stent will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting stent
Description: Paclitaxel-eluting stent will be implanted
Study: NCT04262661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0472-0147
Description: Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0472-0147
Description: Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0472-0147)
Description: Part 1: A single dose of placebo, dose increased in each cohort.
Study: NCT03412786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bcl-Xl_42-CAF09b vaccine
Description: The vaccine consists of 0.05 mg peptide (bcl-xl_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bcl-Xl_42-CAF09b vaccine
Description: The vaccine consists of 0.05 mg peptide (bcl-xl_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion
Study: NCT01563419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indicator magnifying window (Izumi Planning Co.)
Description: IZUMI PLANNING CO,.LTD.Tokyo.Japan~Material: Polypropylene with polycarbonate lens
Study: NCT04323241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled cord traction
Description: In group 2, Spontaneous removal will be performed by massaging on the uterine fundus and applying gentle traction on the umbilical cord.
Study: NCT04542265

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.
Study: NCT01664221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
Study: NCT02043665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21/pembrolizumab
Study: NCT04413136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-ORLA

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT01630681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based stepped care
Description: Interactive support and Cognitive Behavioral Therapy
Study: NCT01268605

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with a dentin bonding agent (DBA)
Description: Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with a resin modified glass ionomer liner (RMGI)
Description: Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
Study: NCT02882685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-y gastric bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single anastomosis gastric bypass
Study: NCT04746300

Intervention type: PROCEDURE
Intervention: Biopsy
Description: A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing

Intervention type: PROCEDURE
Intervention: Biopsy
Description: A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing

Intervention type: PROCEDURE
Intervention: Biopsy
Description: A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood samples will be taken for additional translational research

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood samples will be taken for additional translational research

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood samples will be taken for additional translational research
Study: NCT01949961

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for \~30 minutes, using a Bracco infusion pump.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham ultrasound
Description: Mounting the ultrasound headframe but connecting this to a non-operative channel
Study: NCT02848911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM11
Description: Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks
Study: NCT00399035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XELOX (Capecitabine and Oxaliplatin)
Description: intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cediranib Placebo
Description: oral tablet
Study: NCT00620997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine drops 0.05%
Description: topical, 0.05% drops, PRN continuously for up to 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline drops
Description: saline drops continuously PRN for up to 7 days
Study: NCT02756377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetylpyridinium chloride mouthwash
Description: cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetylpyridinium chloride mouthwash
Description: cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
Study: NCT04114422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seven-day preoperative exercise training program
Description: The preoperative exercise training program will be supervised by a physiotherapist and will comprise aerobic exercise on a treadmill as well as strengthening exercises for the upper and lower limbs. The protocol will include 7 daily sessions of 60 minutes in duration. The treadmill exercise will start with a 5-minute warm-up and will progress to 30 minutes of exercise with a speed corresponding to 70% of the maximum speed reached in the incremental shuttle walk test. It will finish with a 5-minute cool down period. Participants will also perform three strengthening exercises for the lower limbs (hip flexion, knee flexion and extension) and three for the upper limbs (shoulder flexion, elbow flexion and extension). The initial strengthening exercises intensity will be set at 60% of 1RM and will be progressively increased. Patients will perform 3 sets of 8 to 12 repetitions for each exercise.
Study: NCT01852071

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Infusion of autologous EFS-ADA LV CD34+ (OTL-101)
Description: autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Busulfan is used for non-myeloablative conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-ADA ERT
Description: PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
Study: NCT01232712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ImMucin, hGM-CSF
Description: * Six biweekly Intradermal or subcutaneous injections of 100 micrograms ImMucin~* After six injections, if response will not be observed, or if response will not be sufficient, Immucin dose will be escalated to 250 micrograms for six additional injections.~* In addition, each immunization, hGM-CSF with a total dose of 250 microgram will be injected.
Study: NCT01236001

Intervention type: DRUG
Intervention: Lacosamide
Study: NCT00479635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: 160 mg/m2 every three weeks for six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: 160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
Study: NCT00591708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage containing calcium citrate malate
Description: Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage fortified with calcium citrate malate
Description: Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
Study: NCT04238793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLS-2031
Description: KLS-2031 administered by transforaminal epidural injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLS-2031
Description: KLS-2031 administered by transforaminal epidural injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLS-2031
Description: KLS-2031 administered by transforaminal epidural injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9%) administered by transforaminal epidural injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9%) administered by transforaminal epidural injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9%) administered by transforaminal epidural injection
Study: NCT03430258

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-flow nasal cannula
Description: high flow of air with supplemental oxygen was delivered by an Optiflow cannula interface using an AIRVO 2 blower humidifier

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional oxygen therapy
Description: Conventional oxygen therapy
Study: NCT00399035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cediranib Placebo
Description: oral tablet
Study: NCT02714660

Intervention type: OTHER
Intervention: none, observational study
Study: NCT02091076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk fibroin with bioactive coating layer dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bactigras wound dressing
Study: NCT03647683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Compassion
Description: Participants are introduced to the concept of self-compassion. Treating oneself with kindness, while being mindfully aware of the present moment as well as the fact that suffering is part of human life - a shared human experience.~Participants are instructed to use this strategy to cope with the following heat stimulus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance
Description: Participants are introduced to the concept of acceptance. Thoughts, Emotions and Reactions do not need to be related. Being aware of the present moment helps with accepting the present state and reacting contradictory to the thoughts and feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus.
Study: NCT02219724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOXR0916
Description: MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOXR0916
Description: MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
Study: NCT02065024

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: b-cryptoxanthin plus phytosterols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: b-cryptoxanthin plus phytosterols